Ticagrelor (Brilique) for the prevention of atherothrombotic events in adult patients with acute coronary syndromes

Patients treated with ticagrelor + ASA had a 22% reduced risk of all-cause mortality in comparison with patients treated with clopidogrel + ASA. The risk of non-CABGrelated major bleeding was increased by 25% in patients treated with ticagrelor + ASA versus clopidogrel + ASA. Adverse events led to more frequent discontinuation of treatment with ticagrelor than with clopidogrel. More experience has been gained with clopidogrel than with ticagrelor. The dose frequency of clopidogrel is once a day, while the dose frequency of ticagrelor is twice a day. With regard to treatment of patients with acute coronary syndromes, ticagrelor has an added therapeutic value in comparison with clopidogrel. In contrast to the results with prasugrel, treatment with ticagrelor was shown to result in a statistically significant reduction of the risk of all-cause mortality in comparison with treatment with clopidogrel.